BI Asset Management Fondsmaeglerselskab A S Increases Stake in Grifols, S.A. $GRFS

BI Asset Management Fondsmaeglerselskab A S increased its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 466.3% in the first quarter, Holdings Channel.com reports. The firm owned 316,111 shares of the biotechnology company’s stock after purchasing an additional 260,295 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Grifols were worth $2,535,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in GRFS. JPMorgan Chase & Co. lifted its stake in Grifols by 31.8% in the third quarter. JPMorgan Chase & Co. now owns 2,488,294 shares of the biotechnology company’s stock worth $24,783,000 after purchasing an additional 600,118 shares during the last quarter. Integrated Quantitative Investments LLC bought a new position in shares of Grifols during the third quarter valued at approximately $1,361,000. Diversify Wealth Management LLC purchased a new stake in shares of Grifols in the third quarter worth approximately $1,156,000. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Grifols by 31.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 478,769 shares of the biotechnology company’s stock worth $4,476,000 after acquiring an additional 113,539 shares during the last quarter. Finally, Capital World Investors lifted its stake in shares of Grifols by 5.9% during the 3rd quarter. Capital World Investors now owns 22,926,140 shares of the biotechnology company’s stock worth $228,344,000 after acquiring an additional 1,273,391 shares during the last quarter.

Grifols Trading Down 1.4%

GRFS opened at $7.18 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 2.47 and a debt-to-equity ratio of 1.16. The stock’s fifty day moving average is $7.90 and its two-hundred day moving average is $8.50. The company has a market capitalization of $4.89 billion, a P/E ratio of 37.79, a PEG ratio of 0.28 and a beta of 0.65. Grifols, S.A. has a 52 week low of $7.16 and a 52 week high of $11.14.

Grifols (NASDAQ:GRFS) last issued its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share for the quarter. Grifols had a return on equity of 6.21% and a net margin of 5.54%.The business had revenue of $2.32 billion during the quarter. Analysts forecast that Grifols, S.A. will post 1.06 earnings per share for the current year.

Grifols Announces Dividend

The company also recently disclosed a special dividend, which will be paid on Thursday, July 9th. Investors of record on Thursday, July 2nd will be issued a $0.0945 dividend. The ex-dividend date is Thursday, July 2nd. Grifols’s payout ratio is presently 73.68%.

Analysts Set New Price Targets

Several brokerages have commented on GRFS. Zacks Research downgraded Grifols from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Weiss Ratings upgraded Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Finally, Wall Street Zen lowered shares of Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Grifols presently has an average rating of “Reduce” and an average target price of $10.00.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.